ClinicalTrials.gg
CompletedNCT00666835Updated Jul 3, 2023Results posted

Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

A Phase 3 interventional study of HX575 epoetin alfa Hexal AG and ERYPO®, Janssen-Cilag in Anemia, sponsored by Sandoz. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Apr 2004, registered Apr 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Anemia by Novartis — 1 open to participants now, 2 under way, 2 of them phase 3. Anemia · Novartis.

Enrollment
3rd of 17
478 · median 97
Started
2004
with 2 others
Phase 3
12 of 19
1 open now
Registered
5th of 19
by date

Among the 19 studies in Anemia by Novartis, this one is the 3rd largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2004, is one of 12 in phase 3, and was the 5th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 19 studies in Anemia by Novartis is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Anemia by Novartis, or all of them as a file.
02

Study summary

This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia and treated previously with a stable dose of ERYPO® intravenously.

Read the detailed description

The primary objective of this Phase III study is the evaluation of therapeutic equivalence of HX575 Hexal AG and a comparator of epoetin alfa, ERYPO® in the maintenance intravenous treatment of renal anemia. Efficacy, dosage and safety of HX575 Hexal AG in the long-term treatment were assessed.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Treatment of anemia in hemodialysis patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving dialysis for at least 6 months (3 times weekly) before screening
  • Age: >=18
  • Clinically stable, i.e. within the established range (10.0 to 13.0 g/dl) for at least 12 weeks before screening
  • Stable intravenous dosage of ERYPO® three times weekly for at least 8 weeks before screening and during screening with a maximal weekly dosage of 300 IU/kg body weight (stable is defined as \<25% change (up or down) in weekly dose and no change in frequency over 8 weeks prior screening and 10 weeks prior randomisation)
  • Baseline hemoglobin concentration of 10.0 to 13.0 g/dl (mean of two pre-randomization pre-dialysis samples of Hb at visit -2 and visit 1)
  • Serum ferritin >=100 µg/l and/or saturated transferrin levels >=20%
  • C-reactive protein \<15 mg/l (\< 5 mg/l: normal; >= 5 mg/l \< 10 mg/l: +; >=10mg/l \< 100 mg/l: ++; >=100 mg/l: +++)
  • Ability to follow study instructions and likely to complete all required visits
  • Written of the patient

Exclusion criteria

Exclusion Criteria:

  • Anemia of non-renal causes
  • Primary hematologic disorder (e.g. myelodysplastic syndrome, sickle cell anemia, hematological , hemolytic anemia)
  • Evidence of severe hepatic dysfunction ( and/or AST above 2 x ; or gamma-GT above 3 x upper limit of normal range)
  • Clinical evidence of current uncontrolled hyperparathyroidism (serum parathyroid hormone >1500 pg/mL).
  • Known history of bone marrow disease
  • Any red blood cell transfusion(s) during the last 12 weeks before screening or during the screening/baseline period
  • Insufficient concomitant iron treatment during the last 2 months before Visit -2
  • Uncontrolled hypertension, defined as a predialysis diastolic blood pressure measurement >=110 mmHg during the screening period
  • Congestive heart failure [ (NYHA) class III and IV]
  • Unstable angina pectoris, active cardiac disease, cardiac infarction during the last six months before screening
  • History of blood coagulation disease
  • Thrombocytopenia ( count \<100.000/µl)
  • Leukopenia (white blood cell count \< 2.000/µl)
  • Overt bleeding (acute or chronic bleeding within 2 months of inclusion) or hemolysis
  • Evidence of acute infectious disease or serious active inflammatory states within one months before screening (Visit -2) or during the screening/baseline period
  • Suspicion or known PRCA (pure red cell aplasia)
  • Previously diagnosed or acute hepatitis infection
  • Treatment for epilepsy within the past 6 months
  • Planned surgery during the next 7 months (except vascular access surgery)
  • Any androgen therapy within 2 months before visit -2 and during the study
  • Therapy with or any drug known to affect the hematocrit within 1 month before Visit -2 and during the study
  • Clinical evidence of malignant diseases
  • Pregnancy, breastfeeding women or women not using adequate measures
  • Known history of severe drug related allergies
  • Known allergy to one of the ingredients of the test or reference products or to mammalian-derived products
  • Simultaneous participation in another clinical study or participation in a study in the month preceding the start of this study or previously randomized in this study
  • Participation in an erythropoietin study in the 3 months preceding screening (visit -2)
  • Any other condition which at the investigator´s discretion may put the patient at risk or which may confound the study results
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
478 participants (actual)

Study arms

  • Experimental
    HX575 epoetin alfa Hexal AG

    Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.

    Drug: HX575 epoetin alfa Hexal AG

  • Active comparator
    ERYPO®, Janssen-Cilag

    Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.

    Drug: ERYPO®, Janssen-Cilag

Interventions

  • DrugHX575 epoetin alfa Hexal AG

    HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin

    Also known as: Binocrit, Abseamed

  • Solution for i.v. injection

    Also known as: EPREX®, Solution for i.v. injection

06

What researchers measure

Primary outcomes

  1. To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.

    Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.

    Time frame: 28 weeks

Secondary outcomes

  1. Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population

    The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\].

    Time frame: 28 weeks

07

Results

Posted Aug 2, 2017

Participant flow

A total of 568 patients were screened. 479 were eligible for inclusion and were randomized. 478 patients were started on treatment with either epoetin alfa HX575 Hexal AG or ERYPO®, Janssen-Cilag. As the randomization followed a 2:1 scheme, 314 patients received HX575 Hexal AG and 164 patients received ERYPO®.

Participant flow — Overall Study
MilestoneHX575 Epoetin Alfa Hexal AGERYPO®, Janssen-Cilag
Started314164
Completed261142
Not completed5322
Withdrew: Withdrawal by subject52
Withdrew: Lack of efficacy01
Withdrew: Incl./excl. not fulfilled72
Withdrew: Adverse event76
Withdrew: Protocol violation20
Withdrew: Death154
Withdrew: Kidney transplantation (ntx)102
Withdrew: Hemoglobulin concentration43
Withdrew: Planned operation20
Withdrew: Physician decision12

Outcome measures

PrimaryTo Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.

Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.

Time frame:
28 weeks
Reported as:
Least squares mean · g/dL
To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.
g/dLHX575 Epoetin Alfa Hexal AGERYPO®, Janssen-Cilag
To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.0.147 ± 0.0920.063 ± 0.117
Statistical analysis
  • HX575 Epoetin Alfa Hexal AG · Point estimate of difference (ancova): 0.084 · 95% CI -0.170 to 0.338
SecondaryMean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population

The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\].

Time frame:
28 weeks
Reported as:
Least squares mean · g/dL
Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population
g/dLHX575 Epoetin Alfa Hexal AGERYPO®, Janssen-Cilag
Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population0.003 ± 0.079-0.187 ± 0.105
Statistical analysis
  • HX575 Epoetin Alfa Hexal AG vs ERYPO®, Janssen-Cilag · Difference lsm of epo hexal & erypo: 0.189 · 95% CI -0.039 to 0.418

Adverse events

Collected over Recording of AEs included periods before first application and until the end of application of study medication. Occurrence of AEs was recorded from time when patient had given his/her informed consent until the final visit of the main study period (visit 28). By definition, AEs starting in the period after first application until the end of the main period were considered to be 'treatment-emergent' AEs. Analysis based on safety population: patients received at least 1 dose of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HX575 Epoetin Alfa Hexal AG19/314 (6.1%)112/314 (35.7%)283/314 (90.1%)
ERYPO®, Janssen-Cilag5/164 (3%)57/164 (34.8%)154/164 (93.9%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventHX575 Epoetin Alfa Hexal AGERYPO®, Janssen-Cilag
Cardiac and vascular procedural complicationsInjury, poisoning and procedural complications24/31414/164
Ischaemic coronary artery disordersCardiac disorders17/3147/164
Lower respiratory tract and lung infectionsInfections and infestations14/3145/164
Bacterial infections NECInfections and infestations8/3141/164
Peripheral vasoconstriction, necrosis and vascular insufficiencyVascular disorders8/3142/164
Sepsis, bacteraemia and viraemiaInfections and infestations7/3141/164
Rate and rhythm disorders NECCardiac disorders6/3143/164
Cholecystitis and cholelithiasisHepatobiliary disorders3/3143/164
Supraventricular arrhythmiasCardiac disorders5/3140/164
Accelerated and malignant hypertensionVascular disorders5/3141/164
Most frequent other events
Showing 10 of 17
Most frequent other events
EventHX575 Epoetin Alfa Hexal AGERYPO®, Janssen-Cilag
Muscle spasmsMusculoskeletal and connective tissue disorders77/31438/164
NasopharyngitisInfections and infestations55/31435/164
DiarrhoeaGastrointestinal disorders63/31422/164
Haemodialysis-induced symptomInjury, poisoning and procedural complications49/31423/164
HypotensionVascular disorders48/31420/164
Procedural hypotensionInjury, poisoning and procedural complications44/31423/164
BronchitisInfections and infestations28/31419/164
VomitingGastrointestinal disorders27/31418/164
NauseaGastrointestinal disorders30/31414/164
HypertensionVascular disorders29/3149/164

Baseline characteristics

All randomized patients who received at least 1 dose of the study medication and for whom at least 1 post-baseline value of the primary endpoint Hb was available. A prerequisite for patients to be included in the Intention To Treat (ITT) population is that they were treated for four weeks with Hb values available during this period.

Age, Categorical
Age, Categorical(Participants)HX575 Epoetin Alfa Hexal AGERYPO®, Janssen-CilagTotal
<=18 years000
Between 18 and 65 years14584229
>=65 years16980249
Age, Continuous
Age, Continuous(years)HX575 Epoetin Alfa Hexal AGERYPO®, Janssen-CilagTotal
Mean62.3 ± 14.462.6 ± 13.862.4 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)HX575 Epoetin Alfa Hexal AGERYPO®, Janssen-CilagTotal
Female13898236
Male17666242
Region of Enrollment
Region of Enrollment(participants)HX575 Epoetin Alfa Hexal AGERYPO®, Janssen-CilagTotal
Austria7037107
Germany244127371
Body weight
Body weight(kg)HX575 Epoetin Alfa Hexal AGERYPO®, Janssen-CilagTotal
Mean76.3 ± 15.576.0 ± 17.776.2 ± 16.2
08

Study locations

54 sites
  • Landeskrankenhaus Feldkirch
    Feldkirch, Austria
  • Allgemeines Krankenhaus der Barmherzigen Brüder Graz
    Graz, Austria
  • Dialyseinstitut Graz GmbH
    Graz, Austria
  • Krankenhaus der Elisabethinen
    Graz, Austria
  • Universitätsklinik Innsbruck, Klinische Abteilung für Nephrologie
    Innsbruck, Austria
  • Allgemeines Öffentliches Krankenhaus St. Pölten, I. Med. Abteilung
    St. Poelten, Austria
  • Allgemeines öffentliches Krankenhaus Wiener Neustadt , 2. Interne Abteilung
    Vienna, Austria
  • Krankenanstalt Rudolfstiftung der Stadt Wien, 3. Med. Abteilung
    Vienna, Austria
  • Wilhelminenspital der Stadt Wien, Abt. für Nephrologie und Dialyse
    Vienna, Austria
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Aschaffenburg, Germany
  • Dialysepraxis Bad Münder
    Bad Münder, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Bad Nauheim, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Bamberg, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Bayreuth, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Bergisch Gladbach, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Berlin, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Bischofswerda, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Bremerhaven, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Coburg, Germany
  • Dialysepraxis Drs. Riedasch/Schreiber
    Coesfeld, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Deggendorf, Germany
  • Dialysepraxis
    Donaueschingen, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Eberswalde, Germany
  • Dialysepraxis Dr. med. Stefan Holzmann
    Erkelenz, Germany
  • Dialysepraxis Dr. Möller, Dr. Knee
    Essen, Germany
  • Dialysepraxis
    Freiberg, Germany
  • Dialysezentrum
    Freiburg, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Fürstenzell, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Greifswald, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Guenzburg, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Gummersbach, Germany
  • Praxis Dres. Sohn und Schaumann
    Hameln, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Hannover, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Haßfurt, Germany
  • Dialysepraxis Dr. med. Stefan Holzmann
    Heinsberg, Germany
  • Praxis Dr. Kienle
    Homberg, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Ingolstadt, Germany
  • KfH - Prof. Dr. med. Heide Sperschneider
    Jena, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Kronach, Germany
  • Dialysepraxis Dr. med. Matthias Anders
    Leipzig, Germany
  • Kfh Kuratorium für Dialyse & Nierentransplantation e.V., 2.Etage
    Leipzig, Germany
  • KfH Kuratorium für Nierentranplantation und Dialyse e.V.
    Lohr, Germany
  • Dialysepraxis Prof. Rob, Dr. Wilhelm u. Dr. Schümann
    Luebeck, Germany
  • Dialysepraxis Dr.med. H.-D. Hoffmann
    Menden, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Muenchen, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Neuried, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Noerdlingen, Germany
  • Gemeinschaftspraxis Dr.Steger, Dr.Böhmer, Dr.Kirpal
    Nuremberg, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Oberschleißheim, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Plauen, Germany
  • Dialysezentrum
    Potsdam, Germany
  • Praxis Dres.Hartmann, Schiele
    Saarbruecken, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Straubing, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Sulzbach-Rosenberg, Germany
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2004 to primary completion in Jan 2006, 21 months.

Results were first posted in Aug 2017, 11 years 7 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 21 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 25, 2008
StartActual
Apr 2004
Primary completionActual
Jan 2006
CompletionActual
Jan 2006
Results first posted
Aug 2, 2017
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00666835
Lead sponsor
Sandoz
Collaborators
Hexal AG
Responsible party
Sponsor
First posted
Apr 25, 2008
Start date
Apr 2004
Primary completion
Jan 2006
Completion
Jan 2006
Results posted
Aug 2, 2017
Last update
Jul 3, 2023

Study contacts

Marianne Haag-Weber, Prof.
principal investigator · Dialysezentrum Straubing, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion